A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran

Variances in the patients’ outcomes have been a well-documented challenge in anticoagulant therapy. A clinical encounter with a thromboembolic or a hemorrhagic event, due to subtherapeutic or adverse effects of an anticoagulant, is often managed by switching the anticoagulant agent into another, whi...

Full description

Bibliographic Details
Main Authors: Ali Mohammed Abd Alridha, Karrar Mohammed Al-Gburi, Sarah Kadhim Abbood
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Medical Journal of Babylon
Subjects:
Online Access:http://www.medjbabylon.org/article.asp?issn=1812-156X;year=2022;volume=19;issue=3;spage=332;epage=340;aulast=Abd